Pacer Advisors
RNAM

Pacer Advisors’s Avidity Biosciences RNAM Stock Holding History

Pacer Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-622
Closed -$25.4K – 2674
2024
Q2 		$25.4K Sell
622
-309
-33% -$8.87K ﹤0.01% 3382
2024
Q1 		$23.8K Buy
+931
New +$14.6K ﹤0.01% 3411
2021
Q2 		– Sell
-1,417
Closed -$31K – 1536
2021
Q1 		$31K Buy
1,417
+578
+69% +$14.2K ﹤0.01% 1476
2020
Q4 		$21K Buy
+839
New +$24.5K ﹤0.01% 1480

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors's RNAM Position: Q3 2024 in Review

Pacer Advisors sold out of Avidity Biosciences (RNAM) in Q3 2024, closing a stake of 622 shares — an estimated $25.4K sold.

Pacer Advisors first reported a position in RNAM in Q4 2020 and held it in 4 quarters. The position peaked at $31K in Q1 2021. 245 funds tracked by Wall St. Rank hold RNAM as of Q3 2024.

  • Pacer Advisors reported no remaining Avidity Biosciences position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 622 Avidity Biosciences shares in Q3 2024, an estimated $25.4K.
  • Pacer Advisors first reported a position in Avidity Biosciences in Q4 2020 and held it in 4 quarters.
  • Pacer Advisors's Avidity Biosciences position peaked at $31K in Q1 2021.
  • 245 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.